Anti-glomerular basement-membrane (anti-GBM) disease (or Goodpasture disease) is characterized by severe kidney and lung involvement. Prognoses have improved with treatments that combine plasma exchange and immunosuppressive drugs. However, patients with severe renal involvement can have poor renal outcomes and cyclophosphamide can cause significant complications. Anti-GBM antibodies have a direct pathogenic effect on the disease: thus, therapeutics that can decrease their production, such as rituximab, could be a good alternative.
The medical files of five patients that had received rituximab as a first-line therapy (instead of cyclophosphamide), plus plasma exchange and steroids, were reviewed. All patients had severe disease manifestations.
Four patients required dialysis at diagnosis and remained dialysis-dependent over the mean follow-up of 15 months. Three patients had pulmonary involvement, but recovered even though mechanical ventilation was required. Anti-GBM antibodies became rapidly undetectable in all patients. One infectious and two hematological complications were observed.
We report the outcomes of five patients with Goodpasture disease and treated with rituximab as a first-line treatment. This strategy was effective at treating pulmonary manifestations and was associated with a good biological response with no major serious adverse events. However, renal outcomes were not significantly improved.
Cui Z, Zhao MH. Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol. 2011;7:697–705. CrossRef
Fischer EG, Lager DG. Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases. Am J Clin Pathol. 2006;125:445–50. CrossRef
Levy J-B, Turner A-N, Rees A-J, Pusey C-D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134:1033–42. CrossRef
Merkel F, Pullig O, Marx M, Netzer KO, Weber M. Course and prognosis of anti-basement membrane antibody (anti-BM-ab)-mediated disease: report of 35 cases. Nephrol Dial Transplant. 1994;9:372–6. PubMed
Johnson J-P, Moore J, Austin H-A, Balow J-E, Antonovych T-T, Wilson C-B. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine. 1985;64:219–27. CrossRef
Stone J-H, Merkel P-A, Spiera R, Seo P, Langford C-A, Hoffman G-S, et al. RAVE-ITN research group: rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32. CrossRef
Jones R-B, Tervaert J-W-C, Hauser T, Luqmani R, Morgan M-D, Peh C-A, et al. European Vasculitis study group: rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–20. CrossRef
Arzoo K, Sadeghi S, Liebman H-A. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis. 2002;61:922–4. CrossRef
Touzot M, Poisson J, Faguer S, Ribes D, Cohen P, Geffray L, et al. Rituximab in anti-GBM disease: a retrospective study of 8 patients. J Autoimmun. 2015;60:74–9. CrossRef
Syeda U-A, Singer NG, Magrey M. Anti-glomerular basement membrane antibody disease treated with rituximab: a case-based review. Semin Arthritis Rheum. 2013;42:567–72. CrossRef
Sauter M, Schmid H, Anders H-J, Heller F, Weiss M, Sitter T. Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy. Clin Transpl. 2009;23:132–6. CrossRef
Wechsler E, Yang T, Jordan S-C, Vo A, Nast C-C. Anti-glomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol. 2008;4:167–71. CrossRef
Shah Y, Mohiuddin A, Sluman C, Daryanani I, Ledson T, Banerjee A, et al. Rituximab in anti-glomerular basement membrane disease. QJM. 2012;105:195–7. CrossRef
Narayanan M, Casimiro I, Pichler R. A unique way to treat Goodpasture’s disease. BMJ Case Reports 2014; https://doi.org/10.1136/bcr-2014-206220.
Bandak G, Jones B-A, Li J, Yee J, Umanath K. Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy. Clin Kidney J. 2014;7:53–6. CrossRef
Biesenbach P, Kain R, Derfler K, Perkmann T, Soleiman A, Benharkou A, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with Immunoadsorption. PLoS One. 2014;9:e103568. CrossRef
- Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease
P. L. Carron
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II